Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

about

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.

Item

http://www.wikidata.org/entity/Q55323463

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Integrated population pharmaco ...... er patients with solid tumors.

@en

Integrated population pharmaco ...... er patients with solid tumors.

@nl

type

Item

label

Integrated population pharmaco ...... er patients with solid tumors.

@en

Integrated population pharmaco ...... er patients with solid tumors.

@nl

prefLabel

Integrated population pharmaco ...... er patients with solid tumors.

@en

Integrated population pharmaco ...... er patients with solid tumors.

@nl

P1476

Integrated population pharmaco ...... er patients with solid tumors.

@en

P2093

Michael A Eldon

http://www.w3.org/2001/XMLSchema#string

Toufigh Gordi

http://www.w3.org/2001/XMLSchema#string

Ute Hoch

http://www.w3.org/2001/XMLSchema#string

Yen Lin Chia

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Irinotecan (CPT-11) metabolism and disposition in cancer patients.

Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae

P2888

s00280-018-3562-3

P304

897-909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-018-3562-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sherwin Sy

P577

2018-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101676063

http://www.w3.org/2001/XMLSchema#string

P698

29564497

http://www.w3.org/2001/XMLSchema#string

P932

5907632

http://www.w3.org/2001/XMLSchema#string